1. Figure 1 Identification of anti-HLA antibodies
Figure 1 | Identification of anti-HLA antibodies. Traditional cell-based, low-resolution techniques have been the standard method for identification of anti-HLA antibodies in the sera of transplant candidates, but are dependent on the availability of specific cell types and cell viability. Solid-phase testing of sera for HLA antibodies now enables precise identification of each individual HLA antigen against which a patient is sensitized, using techniques based on the Luminex® bead-based multiplex assay principle. The Calculated Panel Reactive Antibody value can be determined from the data obtained from solid-phase assays and is the percentage of historical kidney donors who express any HLA antigen reported as unacceptable because of the patient's antibody specificities. CDC, complement dependent cross-match. Permission obtained from © 2013 Dheda et al.; licensee InTech. Dheda, S. et al. in Current Issues and Future Direction in Kidney Transplantation 1st edn Vol. 1 Ch. 5 (ed. Rath, T.) 105–131 (InTech, 2013).
Michael Cecka, J. (2016) Survival benefits of incompatibleliving donor kidney transplants
Nat. Rev. Nephrol. doi: /nrneph